Skip to main content
Fig. 6 | Biomarker Research

Fig. 6

From: Development of a novel BRCAness score that predicts response to PARP inhibitors

Fig. 6

Association of BRCAness with clinical factors and drug response in breast cancer. A Box plots of BRCAness score by ER-positive/HER2-negative, HER2-positive, and TNBC, in METABRIC, TCGA, and GSE96058. The Kruskal-Wallis test was used to calculate p-values. B Correlation plots of the level of BRCAness and drug sensitivity AUC for olaparib in TNBC and ER-positive/HER2-negative breast cancer cell lines in CCLE data base. Spearman’s rank correlation test was used to perform the analysis. ROC of BRCAness score with AUC in TNBC and ER-positive/HER2-negative breast cancer in (C) GSE25066 cohort (Regimen; taxane and anthracycline) and (D) GSE173839 cohort (Regimen; Durvalumab and olaparib). AUC, area under the curve; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; ROC, Receiver operating characteristic; TNBC, triple negative breast cancer

Back to article page